Still, tipifarnib’s efficacy is contingent on tumor genotype and TME which works best in high HRAS output patients and is ineffective against KRAS-driven cancers unless combined with a geranylgeranyl inhibitor [500] or KRAS-G12 C inhibitor [505]. Here, KRAS is linked to neoplasm.